Patents Examined by Dong Jiang
  • Nucleic acids encoding murine IL-174
    Patent number: 7910331
    Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: March 22, 2011
    Assignee: Schering Corporation
    Inventors: Daniel M. Gorman, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski
  • Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
    Patent number: 7910540
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: March 22, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Rolf E. Kuestner, Zeren Gao, Stephen R. Jaspers, Janine Bilsborough
  • IL-D80 polypeptides and IL-27
    Patent number: 7906622
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: March 15, 2011
    Assignee: Schering Corporation
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • IL-12P40 and IL-B30 polypeptide complex
    Patent number: 7883695
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: February 8, 2011
    Assignee: Schering Corporation
    Inventors: Birgit Oppmann, Rene de Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
  • Anti-human IL-21 monoclonal antibodies
    Patent number: 7883700
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: February 8, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
  • Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
    Patent number: 7871616
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: January 18, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
  • Enhancement of GLP-2 activity of suppressing appetite
    Patent number: 7862824
    Abstract: The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: January 4, 2011
    Assignee: 1149336 Ontario, Inc.
    Inventors: Daniel J. Drucker, Julie Ann Louise Lovshin
  • IL-15 mutants having agonists/antagonists activity
    Patent number: 7858081
    Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLIL68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: December 28, 2010
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jérôme Bernard, Ariane Plet, Yannick Jacques, Catherine Harb, Agnès Quemener, Erwan Mortier
  • IL-17A and IL-17F antagonists
    Patent number: 7842665
    Abstract: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: November 30, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Zeren Gao
  • Use of anti-IL-20 antibody for treating osteoporosis
    Patent number: 7837994
    Abstract: Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: November 23, 2010
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Antibodies that bind hepatocyte growth factor activator
    Patent number: 7825221
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: November 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Yan Wu
  • Antibodies that bind both IL-17A and IL-17F and methods of using the same
    Patent number: 7790163
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
  • Soluble IL-17RA/RC fusion proteins
    Patent number: 7790676
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Gao Zeren
  • IL-17 and IL-23 antagonists and methods of using the same
    Patent number: 7790862
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: September 7, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Steven D. Levin
  • Lipophilic-coated microparticle containing a protein drug and formulation comprising same
    Patent number: 7785625
    Abstract: A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 ?m, comprising a lipophilic substance, hyaluronic acid or an inorganic salt thereof and an active ingredient selected from the group consisting of a protein or peptide drug, retains the full activity of the active ingredient, and when formulated in the form of an oil dispersion or oil-in-water emulsion, it releases in an in vivo environment the active ingredient in a controlled manner over a long period.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: August 31, 2010
    Assignee: LG Life Sciences, Limited
    Inventors: Myung-Jin Kim, Sun-Jin Kim, Kyu-Chan Kwon, Joon Kim
  • Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases
    Patent number: 7786274
    Abstract: This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 31, 2010
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Antibody (11C7) anti nogo a and its pharmaceutical use
    Patent number: 7785593
    Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant <1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: August 31, 2010
    Assignees: Novartis AG, University of Zurich
    Inventors: Carmen Barske, Anis Khusro Mir, Thomas Oertle, Lisa Schnell, Martin E. Schwab, Alessandra Vitaliti, Mauro Zurini
  • Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
    Patent number: 7771719
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: August 10, 2010
    Assignee: Genentech, Inc.
    Inventors: Ellen H. Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Compositions of IL-21 produced in prokaryotic hosts
    Patent number: 7767199
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: August 3, 2010
    Assignee: ZymoGenetics, Inc.
    Inventor: Jeffrey D. Meyer
  • IFN-? production inducing protein (IGIF, IL-18)
    Patent number: 7758853
    Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: July 20, 2010
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Haruki Okamura, Tadao Tanimoto, Kakuji Torigoe, Toshi Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto